Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Tuberculosis is a global health dilemma. In 2016, the WHO reported 10.4 million incidences and 1.7 million deaths. The need to develop new treatments for those infected with Mycobacterium tuberculosis ( Mtb) has led to many large-scale phenotypic screens and many thousands of new active compounds identified in vitro. However, with limited funding, efforts to discover new active molecules against Mtb needs to be more efficient. Several computational machine learning approaches have been shown to have good enrichment and hit rates. We have curated small molecule Mtb data and developed new models with a total of 18,886 molecules with activity cutoffs of 10 μM, 1 μM, and 100 nM. These data sets were used to evaluate different machine learning methods (including deep learning) and metrics and to generate predictions for additional molecules published in 2017. One Mtb model, a combined in vitro and in vivo data Bayesian model at a 100 nM activity yielded the following metrics for 5-fold cross validation: accuracy = 0.88, precision = 0.22, recall = 0.91, specificity = 0.88, kappa = 0.31, and MCC = 0.41. We have also curated an evaluation set ( n = 153 compounds) published in 2017, and when used to test our model, it showed the comparable statistics (accuracy = 0.83, precision = 0.27, recall = 1.00, specificity = 0.81, kappa = 0.36, and MCC = 0.47). We have also compared these models with additional machine learning algorithms showing Bayesian machine learning models constructed with literature Mtb data generated by different laboratories generally were equivalent to or outperformed deep neural networks with external test sets. Finally, we have also compared our training and test sets to show they were suitably diverse and different in order to represent useful evaluation sets. Such Mtb machine learning models could help prioritize compounds for testing in vitro and in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of the predicted and observed secondary structure of T4 phage lysozyme
Matthews, B. W. (1975) · Biochimica et Biophysica Acta (BBA) - Protein Structure · doi:10.1016/0005-2795(75)90109-9 · Cited by 5,399 · cited 2×
“We have included in Assay Central several traditional measurements of model performance, including recall, specificity, precision, F1-Score, Receiver Operating Characteristic (ROC) curve and the area under the curve (AUC), Cohen’s Kappa 50, 51 , and the Matthews correlation 52 .”
MethodChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382 · cited 12×
“A second data set that was compiled was extracted from ChEMBL 31, 32 .”
MethodInfluentialMoleculeNet: a benchmark for molecular machine learning
Wu, Z., Ramsundar, B., Feinberg, E. N., Gomes, J., Geniesse, C., Pappu, A. S., Leswing, K., & Pande, V. (2018) · Chemical Science · doi:10.1039/c7sc02664a · Cited by 3,107
Assessing Agreement on Classification Tasks: The Kappa Statistic
Carletta, J. (1996) · arXiv · doi:10.48550/arxiv.cmp-lg/9602004 · Cited by 2,088
Predicting good probabilities with supervised learning
Niculescu-Mizil, A., & Caruana, R. (2005) · Proceedings of the 22nd international conference on Machine learning - ICML '05 · doi:10.1145/1102351.1102430 · Cited by 1,884
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
From machine learning to deep learning: progress in machine intelligence for rational drug discovery
Zhang, L., Tan, J., Han, D., & Zhu, H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.08.010 · Cited by 760
Deep Learning in Drug Discovery
Gawehn, E., Hiss, J. A., & Schneider, G. (2016) · Molecular Informatics · doi:10.1002/minf.201501008 · Cited by 723 · cited 1×
“This algorithm has also sparked interest in the areas of pharmacology and drug discovery 70 while also stimulating numerous reviews of this still nascent area 29, 71–75 .”
BackgroundApplications of Deep Learning in Biomedicine
Mamoshina, P., Vieira, A., Lane, E., & Zhavoronkov, A. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00982 · Cited by 701
Time-Split Cross-Validation as a Method for Estimating the Goodness of Prospective Prediction.
Sheridan, R. P. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400084k · Cited by 376
Cited by
Exploiting machine learning for end-to-end drug discovery and development
Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0338-z · Cited by 578
Self-citationComparing Multiple Machine Learning Algorithms and Metrics for Estrogen Receptor Binding Prediction
Russo, D. P., Zorn, K. M., Clark, A. M., Zhu, H., & Ekins, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00546 · Cited by 152
Self-citationEbola Virus Bayesian Machine Learning Models Enable New in Vitro Leads
Anantpadma, M., Lane, T., Zorn, K. M., Lingerfelt, M. A., Clark, A. M., Freundlich, J. S., Davey, R. A., Madrid, P. B., & Ekins, S. (2019) · ACS Omega · doi:10.1021/acsomega.8b02948 · Cited by 54
Self-citationDoing it All - How Families are Reshaping Rare Disease Research
Ekins, S., & Perlstein, E. O. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2481-7 · Cited by 10
Self-citation
Metadata
- Authors
- Lane, T., Russo, D. P., Zorn, K. M., Clark, A. M., Korotcov, A., Tkachenko, V., Reynolds, R. C., Perryman, A. L., Freundlich, J. S., & Ekins, S.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-04-19
- Volume
- 15
- Issue
- 10
- Pages
- 4346-4360
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2801291332
- Cited by
- 116
- References
- 11
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. https://app.cochat.ai/papers/10.1021/acs.molpharmaceut.8b00083
- The paper
- Lane, T., Russo, D. P., Zorn, K. M., Clark, A. M., Korotcov, A., Tkachenko, V., Reynolds, R. C., Perryman, A. L., Freundlich, J. S., & Ekins, S. (2018). Comparing and Validating Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.8b00083
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.